InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,446.01
(
0.70%
)
US TECH 100
18,078.72
(
0.73%
)
Dow Jones
40,746.90
(
1.00%
)
Brent Oil
71.50
(
-0.06%
)
Bitcoin
54,956.90
(
0.18%
)

Replies to post #937 on Israel-Medical-Healthcare

Replies to #937 on Israel-Medical-Healthcare
icon url

genisi

04/08/08 5:22 AM

#939 RE: DewDiligence #937

Kamada was granted new (in addition to congenital emphysema and CF) Orphan drug designation by the FDA, for its inhaled AAT for the treatment of Bronchiectasis (currently undergoing Phase II clinical trials).
icon url

genisi

06/03/09 2:05 AM

#1044 RE: DewDiligence #937

Kamada has submitted a BLA to the FDA for its lead clinical candidate, intravenous alpha-1 antitrypsin, for the treatment of AAT.

http://www.globes.co.il/serveen/globes/docview.asp?did=1000454873&fid=942